Pharsight

Xeris patents expiration

1. Gvoke Hypopen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364 XERIS Methods for producing stable therapeutic formulations in aprotic polar solvents
Apr, 2036

(11 years from now)

US11590205 XERIS Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GVOKE HYPOPEN family patents

Family Patents

2. Gvoke Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590205 XERIS Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GVOKE KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Gvoke Pfs patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364 XERIS Methods for producing stable therapeutic formulations in aprotic polar solvents
Apr, 2036

(11 years from now)

US11590205 XERIS Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GVOKE PFS family patents

Family Patents